Abstract
Despite benefit of PARP inhibitors (PARPi) in high grade ovarian cancer (HGOC) a proportion of patients will become resistant. The aim of our study was to assess if AURKA overexpression is a mechanism of PARPi resistant and if the inhibition with alisertib (ALI) could overcome resistance to olaparib (OLA) in cell line models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
